Leaders of the Financial and Economic Committee of the Jiangxi Provincial People's Congress visited our company for research and inspection.

On the morning of December 28, 2020, under the morning sun, Liu Cuilan, member of the Standing Committee of the Jiangxi Provincial People's Congress and Deputy Director of the Finance and Economics Committee, led relevant leaders from various departments to visit our company for research and guidance, accompanied by Chen Qingshou, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Jinggangshan Economic and Technological Development Zone, and Zhang Zhifu, Deputy Director of the Management Committee of Jinggangshan Economic and Technological Development Zone.

The company's General Manager Yao Xiaodong warmly received and conducted an in-depth inspection and research with the visiting leaders at the company's front line. The delegation from the Provincial People's Congress Finance and Economics Committee observed and listened to the on-site production line of tetanus antitoxin, raw material warehouse, and finished product warehouse. He introduced that since the emergence of the biopharmaceutical industry, Jiangxi Bio has promptly tracked the cutting-edge technology of antitoxin serum, deeply cultivated the production and research of biopharmaceutical tetanus antitoxin industry, has unique insights into the development patterns of the biopharmaceutical industry, and possesses keen insight into industry investment opportunities. Jiangxi Bio's professional team actively cooperates with domestic and foreign universities and academicians to provide professional biopharmaceutical industry prevention and treatment services for patients, gaining high recognition from customers. General Manager Yao gave the inspection team a detailed introduction to the progress of new product research and development, showcased pilot samples of new products, and stated that the company has a large amount of first-hand resources and practical experience in antiserum products to support research. Through the company's in-depth development, it will surely lead the company to a new development platform.

Liu Cuilan, member of the Standing Committee of the Provincial People's Congress and Deputy Director of the Finance and Economics Committee, carefully listened and inquired in detail about the company's development situation, and had in-depth exchanges with the company leaders. General Manager Yao Xiaodong provided detailed introductions and answers one by one. Throughout the visit, General Manager Yao gave a serious and detailed work report on the company's product research and development, current development status, technical level, R&D capabilities, platform construction, and future development plans.

General Manager Yao Xiaodong stated that the current biological products mainly include three categories: preventive vaccines, therapeutic antibodies, and biological diagnostic reagents. They play an increasingly important role in diagnosis, prevention, treatment, and even eradication of diseases, protecting human health and extending life expectancy. The company will focus on animal immunoglobulin antibody preparations as the mainstay, aiming to become one of the world's most valuable and competitive modern export-oriented biopharmaceutical enterprises. The leaders of the Provincial People's Congress Finance and Economics Committee expressed appreciation for the company's development and current status. The Finance and Economics Committee inspection team pointed out that the pharmaceutical industry has become the focus of competition among world economic powers, and many countries regard establishing a pharmaceutical industry as a symbol of national strength. The continuous discovery of new drugs and significant advances in treatment methods have brought great changes to the pharmaceutical industry. It is hoped that our company will seize new opportunities in the market economy development, promote the development of the biological products industry through technological innovation, and refine and strengthen the biopharmaceutical industry with technological innovation. Chen Qingshou, Director of the Jinggangshan Economic and Technological Development Zone Management Committee, said during the inspection that the biopharmaceutical industry is a high-investment, high-risk, high-technology, and long-cycle enterprise. It is an emerging industry characterized by knowledge intensity, high technical content, and the high integration and mutual penetration of multiple disciplines. The company must closely follow the latest trends in foreign biopharmaceutical development and research, focus on the establishment of emerging biotechnology industries and the transformation of traditional industries to develop the company's biotechnological drugs, especially strengthening research on projects where the company has technological and resource advantages, enhancing capabilities in technological innovation and product innovation, and gradually forming the district's advantageous technologies and products in the biopharmaceutical field.